Selective Disclosure in Securities Issuance

Selective disclosure is generally a warning sign in securities issuance work because the disclosure regime is built on fairness, broad availability of material information, and confidence in the integrity of the market. However, the law does permit some limited confidential or selective processes in specific contexts. A CCO should be able to distinguish legitimate confidential filing mechanics from problematic selective disclosure practices.

The exam usually tests this area by asking whether a confidential filing, analyst contact, or targeted briefing is permissible, or whether it creates a disclosure and market-integrity concern that requires escalation. The strongest answer focuses on materiality, legal basis, controls, and fairness to the market.

What This Lesson Is Usually Testing

This lesson is usually testing whether the candidate can tell the difference between legally supported confidentiality and unfair selective disclosure.

The main judgment questions are:

• whether the information is material
• whether there is a recognized legal or procedural basis for keeping it non-public
• whether the process still creates an unfair informational advantage

That is why confidentiality agreements and analyst briefings are often trap facts rather than safe answers.

The General Rule: Fair Access to Material Information

In securities issuance work, the starting point is that material information should not be shared selectively with favoured parties in a way that disadvantages the broader market. That is why private briefings with analysts, informal side conversations about offering terms, or special access arrangements for selected investors can be high-risk practices.

Confidentiality agreements do not automatically solve this problem. If the practical effect is that certain market participants receive important information before the public or outside the accepted legal framework, the dealer should treat the practice cautiously. The issue is not only whether the recipient promised secrecy. It is whether the dealer and issuer are using a legally recognized process and controlling misuse of the information.

When Confidentiality or Selective Filing Can Be Legitimate

There are limited situations in which confidential filing or selective treatment is part of the legal framework. The curriculum points to confidential filing mechanisms and certain capital-raising exemptions. The correct exam approach is not to assume that these pathways allow unrestricted selective disclosure. Rather, they can permit a distribution to occur without a prospectus or within a narrower filing and disclosure pathway under defined conditions.

A CCO should still ask whether the issuer and the dealer are staying within the boundaries of the pathway relied upon, whether the information remains properly controlled, and whether the process is being used for a legitimate legal purpose rather than for preferential access.

High-Risk Issuance Practices

The curriculum specifically identifies high-risk practices such as:

• private briefings with analysts
• confidentiality agreements with analysts used in a problematic way
• misuse of confidential filing mechanisms

These practices are high risk because they can create unequal access to material information, increase misrepresentation risk, and undermine confidence in the offering process. A strong CCO answer will usually favour restraint, documentation, legal review, and escalation where the line is unclear.

What Evidence the Dealer Should Have

Where confidentiality or limited disclosure is being used legitimately, the dealer should be able to show:

• why the information is being kept confidential at that stage
• what legal or procedural basis supports the approach
• who has access to the information
• what confidentiality and information-barrier controls apply
• what event ends the confidential treatment or requires public disclosure

If those answers are vague or undocumented, the selective treatment is less likely to be defensible.

    flowchart TD
	    A[Potential selective disclosure] --> B{Is the information material?}
	    B -->|No| C[Continue ordinary control review]
	    B -->|Yes| D{Is there a clear legal or procedural basis for confidentiality?}
	    D -->|No| E[Treat as problematic and escalate]
	    D -->|Yes| F[Apply confidentiality, access, and misuse controls]
	    F --> G{Does the practice still create unfair access?}
	    G -->|Yes| E
	    G -->|No| H[Document and monitor the process]

The main lesson is that confidentiality is not self-justifying. It must be grounded in a recognized process and controlled carefully.

What Stronger Answers Usually Do

Stronger answers usually:

• assess materiality first
• ask whether a clear legal or procedural basis exists for confidentiality
• distinguish controlled confidentiality from selective informational advantage
• escalate quickly when fairness to the market is no longer defensible

That is stronger than saying only that the parties signed confidentiality undertakings.

Common Pitfalls

• Assuming that a confidentiality agreement automatically makes selective disclosure acceptable.
• Treating analyst briefings as low risk if no written material is provided.
• Using confidential filing or exemption-based pathways casually without documenting their legal basis.
• Failing to ask whether the practice creates unfair informational advantage.

Key Takeaways

• Selective disclosure is generally high risk because public offerings depend on fair access to material information.
• Some confidential filing or exemption-based processes are legitimate, but they are narrow and controlled.
• Private briefings, analyst side channels, and casual use of confidentiality agreements are common red flags.
• A confidentiality mechanism is not automatically a defence if the practice still undermines fair disclosure.
• In a scenario, focus on materiality, legal basis, controls, and fairness to the market.

Quiz

Sample Exam Question

An issuer planning a distribution holds private meetings with a small group of analysts and institutional investors to discuss a significant development that has not yet been publicly disclosed. The underwriter argues that the approach is acceptable because everyone in the meetings signs confidentiality agreements and the information will be included in the public documents later if the deal proceeds.

What is the strongest CCO conclusion?

• A. The practice is mainly an investor-relations issue rather than a compliance issue.
• B. The practice is acceptable because confidentiality agreements eliminate any selective-disclosure concern.
• C. The practice is acceptable if no slides are used during the meetings.
• D. The practice is high risk because material information appears to be shared selectively without a clearly justified and tightly controlled legal basis, so the matter should be escalated.

Correct answer: D.

Explanation: The problem is the selective sharing of potentially material information, not simply the lack of documentation. Confidentiality agreements do not automatically make the process defensible. The dealer should ask whether the disclosure pathway is legally supported and whether the practice creates unfair access. Options 1, 3, and 4 all understate the market-integrity and offering-control issues.